v3.26.1
Net Income Per Share (Tables)
 9 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of net income per share for the periods presented:
Three Months Ended March 31,Nine Months Ended March 31,
(in thousands, except per share amounts)
2026202520262025
Numerator:
Net income attributable to common shareholders, basic$21,422 $20,235 $24,649 $28,925 
Change in fair value of warrants(1)
— (13,803)(3,539)(6,160)
Net income attributable to common shareholders, diluted21,422 6,432 21,110 22,765 
Denominator:
Weighted-average common stock outstanding, basic189,455 178,156 187,614 173,462 
Stock options outstanding to purchase shares of common stock including unvested RSUs and from the ESPP691 5,738 1,580 4,518 
Dilutive effect of warrants to purchase common stock335 2,745 1,453 915 
Weighted-average common stock outstanding, diluted
190,481 186,639 190,647 178,895 
Net income per share—basic:$0.11 $0.11 $0.13 $0.17 
Net income per share—diluted:$0.11 $0.03 $0.11 $0.13 
(1) Includes the change in fair value of warrant liabilities to the extent the related warrants to purchase common stock are dilutive or the effect is not anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Income (Loss) Per Share
The weighted average potential shares of common stock that were excluded from the calculation of net income per share-diluted for the periods presented because including them would have been anti-dilutive consisted of the following:
Three Months Ended March 31,Nine Months Ended March 31,
(in thousands)2026202520262025
Stock options outstanding to purchase shares of common stock, unvested RSUs and shares from the ESPP
11,095 2,161 6,932 3,496 

The weighted average potential shares of common stock that were excluded from the calculation of net income per share-diluted because the performance or market conditions associated with these awards were not met are as follows for the periods presented:
Three Months Ended March 31,Nine Months Ended March 31,
(in thousands)2026202520262025
Shares subject to outstanding PVUs
8,439 7,482 8,497 7,422 

The weighted average potential shares of common stock that were excluded from the calculation of net income per share-diluted because the exercise price of the warrants exceeded the average market price of the Company's common stock or the effect would have been anti-dilutive for the periods presented:
Three Months Ended March 31,Nine Months Ended March 31,
(in thousands)2026202520262025
Warrants to purchase shares of common stock18,744 7,241 21,528 4,270